<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23667">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798679</url>
  </required_header>
  <id_info>
    <org_study_id>1602M84521</org_study_id>
    <nct_id>NCT02798679</nct_id>
  </id_info>
  <brief_title>Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity</brief_title>
  <official_title>Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pre-existing cardiac fibrosis is a
      predictor of cancer treatment-related cardiotoxicity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiotoxicity assessed clinically or by cardiac MRI</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Cardiotoxicity</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive participants with breast cancer or lymphoma scheduled to receive
        anthracycline-based chemotherapy or trastuzumab.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage I-III breast cancer or lymphoma with a &gt;2 year life expectancy

          -  A treatment plan that includes anthracyclines and/or trastuzumab

          -  Age &gt;45 years

          -  Able to hold breath for 10 seconds

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

        Exclusion Criteria:

          -  Refusal or inability to provide informed consent

          -  Known heart failure or LVEF &lt;50%

          -  Heart rate over 100 bpm

          -  Renal dysfunction with GFR &lt;30 mL/min/1.73m2

          -  Participants with pacemakers, defibrillators, functioning neurostimulator devices or
             other implanted electronic devices

          -  Symptomatic claustrophobia

          -  Plans to move within 24 months of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chetan Shenoy, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gretchen Peichel, RN</last_name>
    <phone>(612) 626 6237</phone>
    <email>gpeichel@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chetan Shenoy, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 15, 2016</lastchanged_date>
  <firstreceived_date>May 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
